The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.

Cetuximab has an established role in the treatment of patients with recurrent/metastatic colorectal cancer and head and neck squamous cell cancer (HNSCC). However, the long-term effectiveness of cetuximab has been limited by the development of acquired resistance, leading to tumor relapse. By contrast, immunotherapies can elicit long-term tumor regression, but the overall response rates are much more limited. In addition to epidermal growth factor (EGFR) inhibition, cetuximab can activate natural killer (NK) cells to induce antibody-dependent cellular cytotoxicity (ADCC). In view of the above, there is an unmet need for the majority of patients that are treated with both monotherapy cetuximab and immunotherapy. Accumulated evidence from (pre-)clinical studies suggests that targeted therapies can have synergistic antitumor effects through combination with immunotherapy. However, further optimizations, aimed towards illuminating the multifaceted interplay, are required to avoid toxicity and to achieve better therapeutic effectiveness. The current review summarizes existing (pre-)clinical evidence to provide a rationale supporting the use of combined cetuximab and immunotherapy approaches in patients with different types of cancer.

Introduction

The field of cancer treatment has significantly advanced, driven primarily through an increased characterization of the molecular biology, the microenvironment, and the involvement of the immune system in several critical mechanisms of cancer. These advances have led to the development and implementation of targeted and immunotherapies. Targeted therapies are aimed at specifically inhibiting oncogenic signaling pathways that control tumor growth and/or angiogenesis, whereas immunotherapies focus on (re)activating the immune system. Today, both treatment modalities are at the forefront of personalized medicine in cancer treatment.

Several major signaling pathways such as β-catenin, Wnt, phosphatidylinositol 3-kinase (PI3K), and Mitogen-activated protein kinase (MAPK) are recognized for their potentially oncogenic characteristics (1). Among them, the epidermal growth factor receptor (EGFR) is likely the most commonly investigated signaling pathway, renowned for its fundamental role in the tumorigenesis of many cancer types (2). While EGFR expression normally is found between 40 000 to 100 000 receptors/cell (depending on the tissue type), overexpression of EGFR is seen in a majority of cancers, with up to 2 000 000 receptors/cancer cell (3). Thus, downstream signaling of the Ras/Raf/MAPK, PI3K/AKT, JAK/STAT and PLC/PKC pathways is intensified (4), leading to enhanced cellular proliferation, differentiation, survival, migration and motility (5). Inhibition of EGFR has therefore been a compelling topic of research and has led to the development of two classes of anti-EGFR agents: Immunoglobulin G (IgG)-based monoclonal antibodies (mAbs), which competitively bind the ligand-binding site and small-molecule tyrosine kinase inhibitors (TKIs), which compete with adenosine triphosphate (ATP) to bind intracellular EGFR tyrosine kinase domains.

What makes mAbs highly attractive is the ability of IgG1 mAbs to induce antibody-dependent cell-mediated cytotoxicity (ADCC) through Fc receptor-bearing immune cells, increasing tumor immunogenicity and providing a rationale to combine anti-EGFR mAbs with immunotherapies. Cetuximab and necitumumab are the only approved IgG1 mAbs against EGFR (). While cetuximab has been extensively studied in various tumor types (6, 7), literature regarding necitumumab is still limited. Interestingly, similar cytotoxicity has been shown against the DiFi colorectal cancer cell line, due to their affinity for similar EGFR epitopes (8, 9). On the other hand, panitumumab, an IgG2 based anti-EGFR mAb, has similar anti-EGFR activity as cetuximab despite binding different epitopes (10, 11). In monotherapy, the ASPECCT study conducted in chemotherapy-refractory, wild-type KRAS metastatic colorectal cancer (mCRC), showed non-inferiority of panitumumab compared to cetuximab (12). Combined treatment of either cetuximab or panitumumab with irinotecan in platinum-refractory mCRC patients similarly suggested non-inferiority (13). Interestingly, studies directly comparing cetuximab and panitumumab in HNSCC have not been conducted. However, while panitumumab failed to improve OS of HNSCC patients in phase II trials in combination with chemoradiotherapy (14, 15) cetuximab, showed clear benefit in both locally advanced and recurrent and metastatic settings and has been granted approval by regulatory authorities herein (16, 17). Therefore, at least in HNSCC, panitumumab, despite having an increased EGFR-affinity, lacks in clinical activity compared to the highly active potential of cetuximab. A possible reason for this may be explained by the differences linked to the IgG backbone.

Table 1

Summary of approved EGFR-targeted mAbs.

Drug (Trade name)	Company	Indication	Approval FDA/EMA	Isotype	Recommended dose	Clinical trials*
Cetuximab (Erbitux)	Bristol-Myers Squibb	HNSCC,CRC	2004	Chimeric IgG1	I.V. 400 mg/m2 initial, 250 mg/m2 weekly	NCT00004227
						NCT00122460
Panitumumab (Vectibix)	Amgen	CRC	2006/2007	Human IgG2	I.V. 6 mg/kg biweekly	NCT00364013
						NCT00115765
Necitumumab	Eli Lilly and	NSCLC	2015/2016	Human	I.V. 800 mg twice in a	NCT00981058
(Portrazza)	Company			IgG1	3-week cycle	NCT01769391

CRC, colorectal cancer; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; FDA, Food and Drug Administration; HNSCC, head and neck squamous cell carcinoma; I.V., intravenously; NSCLC, non-small cell lung cancer. *Clinical trials upon which approval was based.

As evidenced by prior research, chemotherapeutic agents have immunomodulatory effects, causing (in)direct activation of immune cells due to the release of tumor antigens and certain “danger” signals (18, 19). Targeted therapies are similarly able to reshape the tumor immune microenvironment (TIME) and stimulate the induction of an immune response (20). Immunosurveillance, i.e. the recognition and elimination of malignant cells by the immune system (21), is crucial towards cancer prevention and evasion of immunosurveillance is one of the cancer hallmarks. As the immune system is a complex network of humoral and cellular interactions, alterations in many components of the innate and adaptive immunity lie at hand for tumor evasion (22). In addition, selective survival of tumor cells with a decreased immunogenicity contributes to an evasive tumor growth (23). In this regard, the TIME of several cancers has been characterized, showing both dysfunctional immune cells and a suppressive environment as the main reason for an impaired antitumor immunity (24–27). Based on these principles, immunotherapy has now become a major focus of research in oncology and has led to the implementation of immune checkpoint inhibitors, which have the potential to reawaken silenced immune responses. Recently, several immune checkpoint inhibitors have demonstrated durable response rates and gained Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for use in several oncological indications, including metastatic melanoma, non-small cell lung carcinoma (NSCLC), renal cell carcinoma, head and neck cancer (HNSCC) and colorectal cancer (CRC) (28–30). In the context of EGFR, besides its oncogenic role, EGFR is involved in three main immune-related processes. These include: (1) repression of antigen presentation via downregulation of major histocompatibility complex (MHC) class I and II expression (31); (2) programmed cell death protein (ligand) 1 (PD-1/PD-L1) pathway activation (32); and (3) secretion of immunosuppressive cytokines, such as vascular endothelial growth factor (VEGF), and interleukins (IL) IL-6 and IL-10 (33, 34). Therefore, the use of anti-EGFR therapeutics, such as cetuximab, is a promising strategy of altering the TIME towards tumor recognition and potentially killing rather than evasion and tumor growth.

Although both targeted and immunotherapies are successfully implemented into clinical practice, they present some limitations. In general, when immunotherapies are successful, they can achieve long-term responses in patients. However, response rates with immunotherapies are typically low. In contrast, targeted therapies can achieve much higher initial responses but are lacking in long-term tumor remission, due to the development of resistance. Therefore, growing evidence suggests that combining targeted therapies with immunotherapies can achieve much greater clinical effectiveness for a larger patient population. However, since tumor types vary greatly in their TIME, the applicability of these combinations is dependent on the tumor type and severity of disease (35, 36). For instance, under healthy conditions, all nucleated cells will express MHC class I “self” antigens as a measure of host and non-threat recognition. However, tumor cells often will decrease the expression of MHC-I to evade T-cell recognition of tumor antigens and also their effector functions (37). Therefore, the applicability of T cell-focused immunotherapies is currently complicated by the inability of T cells to recognize MHC-Ineg tumors as well the requirement of neoantigens for the induction of adequate responses. These shortcomings may potentially be circumvented by the innate counterpart of T cells, the natural killer (NK) cells, as they can recognize tumor cells independent of their MHC status and require no presentation of neoantigens. Moreover, NK cell responses can further shape the TIME towards activation of the adaptive immunity, and thus are key effectors of antitumor immunity. In addition, although NK cell infiltration is not equal in all tumor types, the number of tumor-infiltrating NK cells (TINK) has been associated with a significantly better outcome in many tumor types (29, 38–40). Monteverde et al. and others showed that in addition to the number of NK cells, the level of ex vivo antibody-dependent cell-mediated cytotoxicity (ADCC) induction can be used as a predictive biomarker for cetuximab treatment in the clinic (41–43). Together, this shows a unique opportunity for NK cell-based immunotherapy together with anti-EGFR targeted therapeutic approaches to re-establish functional NK cell responses, prime the TIME for the adaptive immunity, and generate more durable antitumor responses.

In this review, we will briefly describe the fundamentals of NK cell biology and functionality followed by a comprehensive review of combination strategies involving EGFR targeted therapies together with immunotherapeutic modalities that aim to restore/enhance the antitumor effects of NK cells. We will focus on cetuximab as an anti-EGFR targeted mAb, as its immune activity has been studied extensively both in monotherapy as well as in combination with other molecules. However, the efficacy of anticancer drugs varies significantly among different tumor types. Therefore, similar or possibly improved results could be achieved with other mAb-based immunotherapies following careful examination and characterization of the TIME.

NK Cell Biology and Antitumor Activity

Grouped among the population of lymphocytes, NK cells share the same progenitor as T and B lymphocytes but differentiate themselves through an antigen-independent activation (44). While the effector function of NK cells overlaps with CD8+ T cells, they do respond to different stimuli and thus complement each other in settings where the effectiveness of one is lacking. Therefore, NK cells, as part of the innate immune system, form the first line of defense against cancer and pathogens (45). In humans, NK cells make up roughly 10-15% of all immune cells (46) and are defined as CD3- CD56+ (47). The two major NK subpopulations are termed CD56bright (high cytokine producers) and CD56dim (high cytotoxicity) NK cells. About 90% of circulating and splenic NK cells are CD56dim, while CD56bright NK cells are mostly present in the secondary lymphoid organs (48). Notably, CD56bright NK cells make up the largest portion of tumor-associated NK cells in several tumor types (48, 49).

Rather than depending on prior antigen presentation, NK cell immunosurveillance is based on a balance between interaction of activating and inhibitory receptors on their surface (50). In this regard, ‘the missing self’ principle (51) describes activation of NK cells through a decreased expression of MHC class I on tumor cells. However, lack of self-recognition alone does not determine NK cell activation and therefore the ‘induced self’ hypothesis describes the requirement of tumor antigens or ligands of activating receptors to be expressed in addition to a reduced self-recognition to establish NK cell activation () (52, 53). A prerequisite for NK cell cytotoxicity is the formation of an immunological synapse, a tight and complex junction formed between an NK cell and its target cell (54). Importantly, FcγRs range in their affinity for human IgGs. The high-affinity FcγRI are therefore able to bind monomeric IgGs while other FcγRs have a low-affinity and are only able to interact with multimeric IgG complexes (55, 56). Following interaction with activating signals, numerous cellular molecules (including receptors, signaling molecules and cellular organelles) will induce cytoskeletal reorganization of NK cells and polarize lytic granules, filled with pore-forming proteins (perforin) and serine proteases (granzymes), towards the synaptic site. Targeted exocytosis of these granules into the synaptic space induces apoptosis in the target cell (57). NK cell activation may occur following interaction with death receptors such as first apoptosis signal (Fas) receptor and tumor necrosis factor (TNF)- related apoptosis-inducing ligand receptor (TRAIL-R) with their ligands, FasL and TRAIL, respectively () (58, 59). In addition, various groups of inhibitory and activating NK cell receptors exist as well, as shown in . Inhibitory NK cell receptors that can recognize MHC-I antigens on tumor cells include the killer Ig-like receptors (KIR2DL and KIR3DL), C-type lectins NK cell group 2 (NKG2A/B) subfamily and leukocyte immunoglobulin-like receptors (LILR) (60, 61). In addition, immune checkpoint receptors, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), PD-1, and the T cell immunoreceptor with Ig and ITIM domains (TIGIT) are present on NK cells as well and prevent sustained activation through inhibitory signaling (62, 63). Interestingly, several of the activating cell surface receptors on NK cells are derived from the same receptor families as their inhibitory counterparts. For example, KIR2DS and KIR3DS belong to the KIR family receptors, while NKG2C/D belong to the C-type lectin family (64). Additionally, the family of natural cytotoxicity receptors (NCR), i.e. NKp46, NKp30, and NKp44, can recognize a broad spectrum of ligands ranging from viral-, parasite- and bacterial-derived to cellular ligands (65). Downstream signaling of NK cell receptors is dependent on the interaction between activating and inhibiting signaling motifs. Activating receptors associated with DNAX-activating protein 10 or 12 (DAP-10/-12) process signals through tyrosine-based signaling motif (YINM) or tyrosine-based activation motif (ITAM) respectively (66). Meanwhile, Inhibitory receptors carry the immunoreceptor tyrosine-based inhibitory motif (ITIM) that overrides DAP-10/-12 signaling and consequently prevents NK cell activation () (67).

Figure 1

Mechanisms of antitumor functionality of NK cells. (A) The represented ‘activating’ and ‘inhibitory’ NK cell receptors determine the NK cell activation through interaction with; (i) stress-induced tumor antigens or ligands for activating receptors acting towards an ‘induced-self’ response or (ii) MHC-I self-antigens or ligands for inhibitory receptors. (B) Additional tumor killing can be induced through either death receptors (FAS/TRAILR/TNFR), or antibody-dependent cellular cytotoxicity (Granzyme B/perforin degranulation). (C) Additional immune modulation by NK cells occurs through secretion of cyto-/chemokines that promote DC maturation and allow crosstalk with T cells, facilitating the induction of an adaptive immune response. Ab, Antibody; DC, Dendritic cell; FasL, Fas ligand; MHC, Major histocompatibility complex; NK, Natural killer; TCR, T-cell receptor; TNF(R), Tumor necrosis factor (receptor); TRAIL(R), TNF-related apoptosis-inducing ligand (receptor).

Figure 2

Representation of NK cell receptor-ligand interactions and signaling motifs that enable downstream cell signaling. (A) The most common NK cell receptor families are illustrated together with their ligands. While some receptors engage multiple ligands, others such as KIR2DL5 and KIR2DS3/S4/S5 have no known ligands. Interaction of ligands with receptors causes activation of downstream signaling pathways. Depending on the type of receptor, this may cause either activation of gene transcription or suppression. (B) Downstream signaling is activated through processing of the receptors-ligand interaction through signaling motifs. Symbols “+” and “-” in the boxes indicate activating and inhibiting signaling. While ITAM and YINM signaling motifs are bound to DAP-10 and -12 adaptor protein respectively, ITIM and HemITAM are present on the receptors and do not require adaptor proteins. The death receptors Fas and TRAIL-R signal through FADD to induce induction of apoptosis in tumor cells. Downstream signaling and gene transcription leading to NK cell activation is dependent on the sum of all activating and inhibiting signals. AICL, Activation-induced C-type lectin; DAP, DNAX-activating protein; DNAM, DNAX accessory molecule; FADD, Fas-associated protein with DD; Grb2, Growth factor receptor-bound protein 2; HemITAM, Hemi-immunoreceptor tyrosine-based activation motif; HLA, Human leukocyte antigen; HSPG, Heparan sulfate proteoglycans; ITAM, Immunoreceptor tyrosine-based activation motif; ITIM, Immunoreceptor tyrosine-based inhibitory motif; KACL; Keratinocyte-associated C-type lectin, KIR, Killer cell immunoglobulin-like receptor; KLRF/G, Killer cell lectin-like receptor F/G; LILRB1, Leukocyte immunoglobulin-like receptor B1 MICA/B, MHC class I polypeptide–related sequence A/B; NCR; Natural cytotoxicity receptors; NK, Natural killer; NKG2, Natural killer group 2; PVR, Poliovirus receptor; SHP1/2, Src homology region 2 domain-containing phosphatase-1; Syk, Spleen tyrosine kinase; TRAIL(R), TNF-related apoptosis-inducing ligand (receptor); ULBP, UL16 binding protein; YINM, Tyrosine-based signaling motif; ZAP70, Zeta-chain associated protein kinase.

Besides direct receptor-ligand interaction, NK cells can become activated by interaction of their Fc receptors (FcγRIIIa/CD16) with the Fc-domain of immunoglobulin G (IgG) antibodies. To achieve subsequent tumor cell killing, the antibody Fab-domain must bind its target on tumor cells to initiate NK cell cytokine and cytotoxic granule secretion, thus inducing ADCC ( and ) (68). Interestingly, ADCC dysfunction has been linked to cancer progression and forms an important mechanism of action for therapeutic mAbs (68, 69). Among the IgG subtypes that have been identified and used to generate antitumor therapies, IgG1-based mAbs have the highest potency to bind with CD16 and thus induce the highest ADCC responses (70). This is evident when comparing clinical data of cetuximab (IgG1) with panitumumab (IgG2) indicating that, although both effectively inhibit EGFR signaling, cetuximab mediates a greater extent of immune-related activity (10, 71). Preclinical models in CD16 deficient mice observed similar antitumor responses between cetuximab and panitumumab due to inhibition of EGFR (72, 73). However, CD16 wild-type mice consistently had enhanced antitumor responses with cetuximab which were linked to its IgG1 backbone (73, 74).

Figure 3

Schematic overview of possible strategies that may be employed to enhance cetuximab-based anticancer NK cell responses. (A) Cetuximab is a mAb that interacts with FcγRIIIa/CD16 receptors on NK cells and EGFR on tumor cells to abrogate EGFR signaling and induce granzyme B and perforin release, causing cell death. (B) NK cell cytotoxicity may be enhanced by additional binding of intracellular EGFR kinase domains that can regulate expression of NK cell receptors. Genetically engineered NK cells such as haNK or CAR-NK have increased natural cytotoxicity and activating signaling which through adoptive transfer can enhance ADCC. Immune checkpoint blockers prevent suppression of NK cell functions by reducing inhibitory signaling while immune agonists aim to increase activating signals. Cytokine stimulation increases NK cell functions and allows an enhanced ADCC response to take place. ADCC; Antibody-dependent cell-mediated cytotoxicity; CAR, Chimeric antigen receptor; EGFR, Epidermal growth factor receptor; IL-2/12/15/21; Interleukin 2/12/15/21; MICA/B, MHC class I polypeptide–related sequence A/B; NKG2D, Natural killer group 2D; PD-1, Programmed cell death protein 1; PD-L1, Programmed death-ligand 1; PRR; Pathogen recognition receptors; ScFv, Single-chain variable fragment TKI; Tyrosine kinase inhibitor; ULBP, UL16 binding protein.

Aside from IgG subtypes, other factors related to interindividual heterogeneity rather than the composition of the mAb can affect ADCC by NK cells. First, FcyRIIIa gene polymorphisms are the most well-known factor in this regard. Individuals possessing the 158V/V allotype induce higher ADCC responses in various tumor types compared to individuals with the 158V/F or 158F/F allotypes (42, 75, 76). , transduction of the human NK-92 cell line with the 158V/V allotype (high-affinity NK; haNK) increased natural cytotoxicity, cetuximab-induced ADCC (77) and cytokine secretion (78). Second, the presence of immunosuppressive cytokines, such as transforming growth factor β (TGF-β) or IL-10 or increased signaling through inhibitory KIR receptors or NKG2A, provides additional inhibitory signals. This shifts the balance of NK cell activity towards an inhibitory state, preventing the induction of ADCC (79–81). Third, while cetuximab resistance mechanisms limit the effectiveness of anti-EGFR treatments and promote tumor cell survival, they are unable to prevent granzyme B (GZMB)-induced apoptosis by healthy NK cells following cetuximab treatment (82–85). On the other hand, EGFR-independent resistance mechanisms against immune cell-mediated cell death have been described (86). For example, the presence of tumor cells expressing serine protease inhibitor-9 (PI-9), an irreversible inhibitor of GZMB, correlated with a poorer outcome in melanoma patients (87, 88). Overexpression of X-linked inhibitor of apoptosis protein (XIAP), a potent caspase inhibitor, in breast cancer induced resistance to cetuximab-mediated ADCC in both a caspase-dependent and -independent manner (via accumulation of reactive oxygen species) (89). Lastly, activation of autophagy under hypoxic conditions showed beclin-1-mediated degradation of NK cell-derived GZMB in vitro, which compromised the ability of NK cells to eliminate breast cancer cell lines (90). Notwithstanding these variable factors, the ability for ADCC remains a valuable and promising option in the therapeutic armamentarium, favoring mAbs such as cetuximab.

Next to direct activation, indirect NK cell activation primes NK cells towards activation by increasing the expression of activating receptors, reducing the threshold for activation and reducing the responsiveness to inhibitory signals (91). This can be achieved through interaction with mature dendritic cells (DC) or cytokines such as IL-2, IL-12, IL-15, IL-18, IL-21 and type-I interferons (92, 93). However, vice versa, activated NK cells can cross-talk with DC, promoting their maturation and subsequent CD8+ T cell priming, resulting in the generation of tumor-specific T cells that contribute to the antitumor immune reaction () (94). As such, in addition to tumor elimination, NK cells also modulate and shape antitumor immunity, showing their crucial role to achieve tumor elimination.

Strategies to Enhance Cetuximab Driven Immune Activity

Initial preclinical models showed that efficacy of cetuximab on inhibition of the downstream effectors and interfering with tumor cell proliferation could be further enhanced through combination with conventional therapies, such as radiotherapy or chemotherapy (16, 95, 96). Later, it became apparent that this enhancement was in part attributable to an immunological response through an enhanced tumor infiltration of immune cells and ADCC (97, 98). However, there is evidence to suggest that TINK cells reside in an impaired state and only induce limited activity (99, 100). Furthermore, NK cell immune evasion by tumor cells has been described to be caused through two main mechanisms: (1) reduction of activating ligands on tumor cells; and (2) a dominance of NK cell inhibitory signals, preventing downstream signaling of activating signals. In addition, additional immunosuppressive mechanisms from bystander regulatory immune cells can further stimulate tumor progression (101). Therefore, in describing NK cell immunosurveillance enhancements, applicability depends on the composition of the TIME of different tumor types. Re-establishing NK cell functionality thus is a topic of great interest, as it could improve the antitumor immune responses observed in the clinic. In this regard, the research mainly focuses on two major approaches: (1) increasing signaling through immunoreceptor tyrosine-based activation motif (ITAM/YINM)-containing receptors; and (2) decreasing signaling and cross-linking of inhibitory motif (ITIM)-containing receptors. Below, we discuss several strategies to potentiate NK cells to elevate cetuximab efficacy to the next level ().

Dual Inhibition of EGFR Extracellular and Intracellular Domains

Despite initial promising results observed with anti-EGFR treatments, the most prominent limiting factor of its clinical effectiveness is the presence/development of drug resistance. Research has considerably focused on unraveling mechanisms behind this resistance and results have shown various ways to prevent/overcome EGFR-resistance (102–105). Of these, simultaneous inhibition of extracellular and intracellular domains of EGFR has been suggested to increase the overall antitumor effects. In this regard, the combined use of cetuximab and erlotinib/gefitinib induced synergistic antitumor effects with decreased proliferation and increased apoptosis in various human cell lines (106, 107). Phase I/II trials in NSCLC and CRC using combined treatment of cetuximab with gefitinib or erlotinib reported no additional toxicities with moderately enhanced antitumor effects (107–110). Even better results were obtained with second (afatinib) and third-generation (osimertinib) anti-EGFR TKIs in combination with cetuximab (111, 112). Additionally, the sequential treatment of NSCLC patients in a phase I trial using sequential treatment of afatinib and cetuximab observed improved objective response rates and progression-free survival (PFS) (111).

Besides an improved antitumor effect, it was also suggested that combined targeting of extracellular and intracellular domains of EGFR could improve immunologic responses. While the immunological effects of mAbs are well described, the therapeutic effect of EGFR TKIs has been predominantly attributed to the inhibition of signal transduction. However, current knowledge suggests that TKIs might indirectly be involved in antitumor immune responses. For example, treatment of NSCLC and CRC cells with the anti-EGFR TKI gefitinib or erlotinib increased natural cytotoxicity of NK cells through upregulation of NKG2D ligands ULBP-1/-2 and MHC class I polypeptide–related sequence (MIC)A/B (113–116), and downregulation of PD-L1 expression (117). In contrast, another study reported downregulated MICB and ULBP–2/5/6 expression following treatment with erlotinib (118). This indirect immunomodulatory effect suggests that simultaneous inhibition of extracellular and intracellular EGFR domains could increase antitumoral effects, due to dual targeting of EGFR, and improve immunologic responses as well. Indeed, combined treatment with cetuximab and erlotinib improved NK cell activity in NSCLC cell lines and an NSCLC mouse model through an improved ADCC response (119). This is likely caused by an increased expression of the NKG2D ligands by EGFR-TKI (119), which shifts the balance towards NK cell activity. Together with cetuximab-induced ADCC, this shift increases the overall cytotoxic activity of NK cells. A similar study in ovarian cancer cell lines observed enhanced antitumor responses and increased sensitivity towards cetuximab-induced ADCC following treatment with either erlotinib or gefitinib, even in tumor cells that were either intrinsically or acquired resistant to either TKI treatment (120).

One key consideration is the potential for overlapping toxicities of dual EGFR inhibition. However, most trials observe manageable toxicities, with one trial in particular reporting a similar percentage of grade 3/4 adverse events (AEs) when afatinib was combined with cetuximab simultaneously compared to sequential treatment or either treatment alone. However, the overall incidence of AEs was higher in the combination regimen (121). As clinical doses are based on toxicity and not target inhibition, the tolerable doses of each agent in the combination may be suboptimal. However, further clinical investigation is warranted to compare the observed toxicity profile with the effectiveness of this combination.

Adoptive Transfer Therapy Using (un)Modified NK Cells

Adoptive Transfer of Autologous Expanded NK Cells

As NK cells are often impaired in cancer patients, the use of adoptive NK cellular immunotherapy aims to restore NK cell functionality through supplementation or complete replacement of the NK cell populations with functionally active NK cells. As a result, tumor load, and the immunosuppressive TIME could be reduced. Earliest attempts of adoptive NK cell transfer failed to show meaningful clinical responses using ex vivo purified and unstimulated NK cells (122).

Therefore, combination of an NK cellular product with cetuximab could enhance the functionality of these NK cells and achieve overall responses through the induction of ADCC. A phase I trial in CRC administered ex vivo expanded patient-derived NK cells following cetuximab treatment (123). Noteworthy, the majority of expanded NK cells showed high expression of NKG2D and CD16, and high lymphocyte-activation gene 3 (LAG-3) and TIGIT expression. Cytotoxic effects toward the tumor remained elevated up to 4 weeks following NK cell administration, indicating a favor towards NK activation rather than inhibition. Addition of expanded NK cells following cetuximab treatment displayed an increased cytotoxic activity against tumor cell lines and reduced overall tumor size of heavily pretreated cetuximab-resistant patients. Lastly, patients treated with expanded NK cells following cetuximab showed enriched levels of circulating interferon gamma (IFNγ) and reduced Treg frequencies, suggesting an induction of a Th1‐type adaptive immune response (123).

Adoptive Transfer of Allogeneic Expanded NK Cells

With the increased understanding of self-regulation in NK cells, a possible alternative for the limited number of patient-derived NK cells has been the use of allogeneic NK cells. This approach may hold several benefits including the ability to obtain NK cells from healthy donors which may retain greater antitumor activity and the development of off-the-shelf application due to easier and greater availability of NK cells (124). Furthermore, several models to predict alloreactivity of NK cells (graft-versus-host disease) have been described (125), the ‘Receptor–ligand mismatch’ model remains one the most established predictive models. Briefly, donor NK cells bearing inhibitory KIR for which the corresponding HLA ligands are missing in the recipient become uninhibited. The presence of (non-HLA-restricted) activating signals can then induce alloreactivity (126, 127).

Sources for alloreactive NK cells include (i) acquiring umbilical cord blood (128),; (ii) partially KIR/HLA matched peripheral blood (126); or (iii) engineered NK cell lines (129). Investigations using the former primary NK cells yielded increased expression of activation markers CD69 and CD16 and strong ADCC responses towards NSCLC and B cell lymphoma in vitro and in mice (128). Adoptive transfer of the modified NK-92 cell line (haNK) cells with cetuximab harbored the capacity to efficiently kill HNSCC tumor cells in a dose-dependent manner and enhanced ADCC response (130, 131). In a clinical trial in NSCLC, ex vivo stimulated KIR/HLA matched healthy donor NK cells were administered together with cetuximab. This combination led to a significantly improved PFS and OS compared to cetuximab alone (132). A phase I trial in gastrointestinal carcinoma used allogeneic IL-2 stimulated NK cells in combination with cetuximab and obtained beneficial clinical responses and a tolerable safety profile (133). Interestingly, while addition of adoptive NK cells increased the number of circulating lymphocytes (CD8+, CD4+, B and NK cells), cetuximab alone, albeit to a lesser degree, was also able to significantly increase lymphocyte levels. This suggests that part of the increased levels may be related to improvement of cellular immunity and prevention of apoptosis of T cells. Indeed, levels of IFNγ and pro-inflammatory cytokines were significantly more present through combination of cetuximab with adoptive NK cell transfer, indicating an enhanced Th1-response (132). These first and promising results of cetuximab stimulating adoptive NK cell therapy in solid tumors are encouraging, since to date clinical effectiveness of adoptive NK cell therapy is only observed in hematological malignancies. Therefore, more research on cetuximab unlocking the potential of adoptive NK cell therapy for solid tumors is warranted.

Chimeric Antigen Receptor (CAR)-Engineered NK Cells

A more recent and promising approach for adoptive NK cell therapy is the use of chimeric antigen receptor-engineered NK (CAR-NK) cells. These can be developed either through lenti-/retroviral transduction of primary adult NK cells or immortalized NK-92 cells to recognize a specific tumor antigen (134). CAR-NK cells have several advantages over CAR-T cells. First, they are more robust as they still maintain their intrinsic target cell recognition. Therefore, a reduction of the target CAR is less likely to be an effective tumor escape mechanism (135). Second, cytokines released by activated NK cells are less associated with the induction of a cytokine release syndrome (136, 137). Third, as NK cells do not clonally expand, the cytokine levels they release is found to be less sufficient to induce a cytokine release syndrome (138, 139). Fourth, NK cells are known to suppress graft-versus-host reactions which are induced by T cells due to strict HLA-matching (135, 136, 138).

While CAR-NK therapy research is developing at a rapid pace, combination treatments using CAR-NK together with already established treatments are still limited. Recently, combined treatment of a CRC mouse model with epithelial cell adhesion molecule (EpCAM)-CAR-NK-92 and regorafenib (a sorafenib-related multikinase inhibitor) achieved a synergistic tumor suppression than either treatment alone (140). The basis for this investigation was the observation that regorafenib could modulate the TIME through alteration of Fas and PD-L1 expression in CRC cell lines (140). Similarly, efficacy of cetuximab in HNSCC is also linked to its immunostimulatory activities which include downregulation of PD-L1 expression. Therefore, although not validated yet, this suggests that cetuximab combined with CAR-NK cells against a specific tumor antigen could alter the TIME towards tumor cell killing as a potentially promising treatment strategy. As a proof of concept, CAR-T cells transduced with CD32A or CD16 in combination with cetuximab, achieved a greater cytotoxic response and improved survival of a CRC mouse model bearing EGFR mutations compared to either treatment alone (141, 142). Taken together, although definitive evidence for this regimen is still missing, these early results support the potential strength of cetuximab-based dual-targeting CAR-NK therapy as an adoptive therapy.

A last consideration is that adoptive transfer of (un)modified NK cells in solid tumors is inferior compared to responses observed in hematological malignancies. The most evident cause for this discrepancy is the poor migration of infused NK cells inside the tumor. This may be caused by altered chemokine receptors following ex vivo activation. For example, CXCR2/3/4 are important chemokine receptors on immune cells that facilitate migration towards CXCL9/10/12-expressing tumor cells (143–146). Loss of CXCR2/3 following ex vivo activation prevented NK cells from migrating towards B16 melanoma tumors (147). Therefore, more recent expansion protocols such as the one described by Somanchi et al. (148) consider the chemokine repertoire in order to achieve efficient expansions of specific NK cell phenotypes that may provide a better invasion in the tumor.

Targeting Negative Immune Checkpoint Molecules Prevents Immune Escape

Discovery of immune checkpoint blockade has played a pivotal role towards integration of immunotherapy into clinical cancer treatment. While initial immune checkpoint inhibitors, such as anti-CTLA-4 (ipilimumab) and anti-PD-1 (pembrolizumab) have focused on reversing the suppressed state of cytotoxic T cells (149), current research is expanding this to other cell types, including NK cells (). This expanded research also brought with it an increasing number of molecules that are being investigated as possible immune checkpoints and an endless possibility for combinations with checkpoint inhibitors to achieve greater responses.

Figure 4

Targeting immune regulatory molecules improves immune effector function against cancer. NK cell activity is regulated by a balance between immune activating and inhibiting interactions. Cancer promotes immune checkpoint expression to suppress NK cell activation allowing tumor immune escape and progression. Antibody-based immunotherapies suppress inhibitory signaling or further activate costimulatory signals to restore and enhance NK cell activity. HLA, Human leukocyte antigen; KIR, Killer cell immunoglobulin-like receptor; LILRB1, Leukocyte immunoglobulin-like receptor B1; NK, Natural killer; NKG2A, Natural killer group 2A; PD-1, Programmed cell death protein 1; PD-L1, Programmed cell death ligand 1; TIGIT, T cell immunoreceptor with Ig and ITIM domains.

Programmed Cell Death Protein 1 (PD-1) Pathway

The PD-1/PD-L1 axis has become one of the most studied pathways in cancer immunotherapy, with promising results guiding the approval of several inhibitors (150, 151). Interestingly, early investigations of PD-1 expression on NK cells found 25% of healthy individuals to have PD-1+ NK cells which correlated well with prior human cytomegalovirus infections (152). This prompted the idea that PD-1 expression on NK cells is a result of activation rather than exhaustion, which is the case for T cells following chronic stimulation (153). In cancer patients, peripheral blood NK cells are often found to be PD-1 positive (154–156) and intratumoral NK cells often express high levels of PD-1 (40, 156).

Interestingly, PD-1+ NK cells were found to have downregulated CD16 expression and induce PD-L1 expression on tumor cells via IFNγ secretion, thus possibly inhibiting ADCC induction (157). However, inhibition of EGFR-signaling via cetuximab is known to interrupt INF-γ signaling and prevent PD-L1 upregulation on tumor cells (117). Thus, combining cetuximab with a PD-1 inhibitor could be viewed as a valuable strategy to prevent CD16 downregulation and PD-1/PD-L1-axis mediated silencing of ADCC. A study in HNSCC found an increased number of PD-1+ NK cells in patients, which correlated with a diminished NK cell activity, as observed by a downregulated expression of CD16, CD107a and GZMB. In addition, PD-L1 expression correlated with a lack of response to cetuximab alone. Administration of cetuximab in combination with the anti-PD-1 mAb nivolumab successfully reversed NK cell diminishment and enhanced cetuximab-mediated ADCC in vitro (157). Early results from a phase I trial in HNSCC patients also reported an increased objective response rate compared to either treatment alone (158). Currently, several trials investigating this combination are ongoing, with preliminary results indicating potentially synergistic effects in advanced solid tumors (159, 160).

T Cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Pathway

Recent years have seen a growing interest in the TIGIT signaling pathway due to its complex immunomodulatory role. Similar to the B7/CD28/CTLA-4 pathway, the TIGIT axis consists of a network of inhibitory receptors (TIGIT, CD96 and CD112R) that compete with the activating receptor (DNAM-1/CD226) for their shared ligands (CD111/NECTIN1, CD112/NECTIN2, CD113/NECTIN3, CD155/PVR) (161, 162). In contrast to DNAM-1, only marginal TIGIT expression is observed on resting NK and T cells while stimulation and tumor infiltration showed upregulated TIGIT expression (161). As a stimulatory receptor, DNAM-1 signaling induces pro-inflammatory cytokine secretion and enhances cytotoxic activity of NK cells. Meanwhile, TIGIT induces an anti-inflammatory, non-proliferative and non-cytotoxic profile in NK cells (163).

Targeting of TIGIT is still in early development but positive early (pre)clinical investigations have enabled further clinical investigations. Interestingly, in vitro co-culture and in vivo transgenic HNSCC mice models were able to restore the cytotoxic effects of T and NK cells following anti-TIGIT treatment (164). Initial clinical studies in solid tumors demonstrated strong antitumor activity as a single agent (163, 165), that could be further improved when combined with anti-PD1 mAb (NCT03119428, NCT02794571). Furthermore, disruption of the TIGIT/CD155 interaction can also beneficially impact the TIME, in particular by incapacitating myeloid-derived suppressor cells and depleting Tregs. Although not investigated yet, this observation suggests the possible combination of anti-TIGIT-mAbs with cetuximab, thereby reducing the suppressive action of Tregs and targeting specific tumor antigens.

Alternatively to TIGIT, CD155 (PVR), has been suggested as a potential target due to its greater affinity towards TIGIT compared to DNAM-1 and its frequent overexpression in solid tumors (166, 167). However, clinical trials of CD155 are still scarce and preclinical investigations of CD155 in combination with cetuximab are limited as well. However, one study in CRC cell lines reported an improvement of cetuximab-mediated ADCC following effective signaling of DNAM-1/CD155. Blocking this interaction abrogated this effect entirely (168). The same effect was observed by blocking NKG2D/MICA/B signaling. A possible reason for the limited progress in CD155 targeting might be that CD155 inhibition disrupts both TIGIT and DNAM-1 signaling, therefore potentially robbing NK cells from activating signals. However, this concern is not completely warranted, as CD155 under normal circumstances has a greater affinity towards inhibitory receptors, thus preferentially signaling via TIGIT even in the presence of DNAM-1 (169). Lastly, administration of anti-CD155 also showed upregulation of DNAM-1 on peripheral blood lymphocytes. As CD155 is not the only ligand capable of binding DNAM-1, this interaction could potentially shift the balance towards increased antitumor immunity (170).

Altogether, this suggests that strategies targeting the TIGIT-axis could reverse immune inhibition through reduced inhibitory signaling and that combinations with cetuximab could enhance ADCC, resulting in an enhanced antitumor response (167).

C-Type Lectin NK Cell Group 2 (NKG2) Subfamily Pathway

Another ITIM-containing signaling pathway expressed on NK and T cells is the NKG2A-HLA-E interaction. Although NKG2A is expressed on a low number of peripheral NK cells, both antigen and cytokine stimulation upregulate its expression (171, 172). While binding of NKG2A to HLA-E is known to inhibit NK cell responses, ovarian cancer cell lines that were treated with the anti-NKG2A mAb monalizumab showed profound antitumor responses and significantly improved cetuximab-mediated ADCC (173, 174). Moreover, monalizumab combined with cetuximab was tested in a phase II trial with recurrent and metastatic HNSCC patients showing promising improvements with an easily manageable safety profile similar to either treatment alone (173). Another trial, where monalizumab was combined with durvalumab (anti-PD-1 mAb) in CRC showed encouraging activity as well (175). Meanwhile, a phase III randomized trial in HNSCC has been announced for this combination (176). Therefore, an anti-NKG2A mAb could be a promising checkpoint inhibitor to enhance antitumor immunity of both T and NK cells.

Killer-Cell Immunoglobulin-Like Receptor (KIR) Pathway

KIRs play a major role in regulating NK cell activity through various inhibitory and activating receptors and are most frequently found on intratumoral CD56dim NK cells (29, 171). Similar to IFNγ, the inhibition of EGFR can increase HLA-C expression through STAT-1 signaling (26, 177). Thus, this could potentially limit NK cell responses through an increased interaction of KIRs with HLA-C. The use of mAbs, such as lirilumab (IPH2102), targeting KIR2DL-1/-2/-3, can mimic the mismatch of KIR with HLA-C and prevent inhibitory signaling. Indeed, various (pre-)clinical reports have described an improved NK cell cytotoxicity following lirilumab treatment (178–180). Furthermore, combination of lirilumab with an anti-CD20 mAb enhanced ADCC against lymphoma cells in vitro and in vivo (180). Similarly, lirilumab in combination with cetuximab induced a significantly higher cytotoxic response against HNSCC cell lines in co-culture experiments (149). Hence, despite the lack of extensive literature, investigations of lirilumab in combination with cetuximab suggest that could generate clinical benefit and therefore warrant further investigation. Importantly however, long-term treatment with lirilumab may also hold some drawbacks. To fully develop into functionally mature cells, NK cells undergo a process of ‘education’ whereby their level of exposure and interaction to ‘self’ antigens with inhibitory receptors will determine their responsiveness in cases where these antigens are missing (181). Therefore, it is thought that persistent inhibition of KIRs could, besides stimulating the activity of mature NK cells, impede the development of new, functionally competent NK cells (178). In this regard, future clinical trials will have to resolve the optimal scheduling of blockade of inhibitory receptors.

Leukocyte Immunoglobulin-Like Receptor B (LILRB) Pathway

Similar to KIRs although far less understood, leukocyte immunoglobulin‐like receptors (LILRs)can regulate immune activity through ligation with MHC class I molecules. However, in contrast to the extensive KIR repertoire being expressed, NK cells predominantly express LILRB1 (182, 183). Interestingly, LILRB1 expression negatively correlated with cetuximab-induced ADCC against breast cancer patients (184). Furthermore, blocking LILRB1 increased both natural cytotoxicity as well as cetuximab-mediated ADCC, especially when both NK cells and cancer cells expressed LILRB1. Interestingly, LILRB1 expression and cetuximab-mediated ADCC were positively correlated in this context, indicating a greater inhibition at higher LILRB1 expression levels. However, LILRB1 research is still limited and factors impacting the regulation of LILRB1 expression should be the focus of future research to assess the potential for clinical implementation of this combination.

Immune Agonists Allow Positive Immune Checkpoint Therapy

Since NK cells are dependent on a balance between positive and negative signals, negative signaling from immune checkpoints is counterbalanced by immune stimulatory molecules that positively enhance antitumor responses. Early attempts of developing potent agonist therapies were met with tremendous clinical toxicities due to selection of CD28, a constitutively expressed ‘second signal’ receptor on T cells, as a target. Theralizumab, despite the promising preclinical results, induced severe cytokine release syndrome with a high proportion of multiple organ failure in a phase I trial (185). Therefore, cautioned and rational selection of stimulatory molecules is essential to prevent non-discriminatory immune stimulation. Current approaches mostly comprise of selecting inducible targets following stimulation or maturation, rather than constitutive expression by immune cells (186).

Tumor Necrosis Factor Receptor Superfamily Member 9 (CD137/TNFRSF9)

Of interest for the context of this review is the molecule CD137 (4-1BB), expressed on various immune cells following pro-inflammatory stimuli (187). Signaling through CD137 delivers an enhanced tumor-selective cytotoxicity and IFNγ secretion (188). Interestingly, CD137 agonistic mAbs are classified as either strong or weak agonistic Abs. The difference is that strong agonistic Abs (Urelumab) can activate 4-1BB without FcγR-mediated crosslinking, while the weak agonistic Abs (Utomilumab) require FcγR-mediated crosslinking to activate 4-1BB. However, the effects of both classes can still be enhanced through separate FcγR-crosslinking (189). In this regard, although urelumab alone in a breast cancer xenograft model had no effect on tumor size, combined treatment with trastuzumab enhanced trastuzumab-mediated killing significantly (190). Furthermore, urelumab together with cetuximab greatly improved survival of HNSCC patients and elevated DC maturation and T cell cross-presentation together with an increased cytokine secretion (185, 186). Interestingly, TINK but not peripheral blood NK cells substantially increased CD137 expression following treatment with cetuximab. Both urelumab and cetuximab alone also upregulated anti-apoptotic proteins (Bcl-xL and Bcl-2) in NK cells, suggesting an improved survival of activated NK cells, that was further increased following combination treatment (186). These results suggest that urelumab could indeed be combined with cetuximab to enhance immune activity. However, the early clinical observations remain to be investigated in larger cohorts and various tumor types to develop a stronger support for this notion.

Pattern Recognition Receptors (PRR)

A critical role in pathogen recognition is carried out by toll-like receptors (TLRs). As part of the innate immunity, TLRs play a vital role in activating immune responses as well. This is achieved through recognition of pathogen- or damage-associated molecular patterns (PAMPs and DAMPs) expressed by microorganisms or released from damaged or dying cells (191). While a total of 11 TLRs have been identified, TLR7/8 are of particular interest in cancer research due to their direct immune stimulatory effect and simultaneous ablation of Treg function (192, 193). Therefore, stimulation of TLR7/8 could be an interesting treatment in tumors that are highly infiltrated with effector and suppressive immune cells. Stimulation through TLR7/8 could potentially polarize the TIME towards tumor killing by producing Th1-polarizing cytokines such as TNF-α, IFNγ and IL-12 (192). In this regard, the use of the TLR8 agonist motolimod, increased peripheral blood mononuclear cell cytotoxicity against HNSCC cell lines, together with a higher production of inflammatory cytokines and chemokines by DCs, monocytes and NK cells (194). Additionally, ADCC was enhanced through combination with cetuximab as well (194, 195), showing a possible way to effectively activate innate and adaptive anticancer immune responses. A phase I trial in HNSCC reported encouraging antitumor activity without dose limiting toxicities when motolimod was combined with cetuximab. Furthermore, increases in plasma cytokine levels and in frequency and activation of circulating NK cells were observed as well (196). Currently, this combination is being further investigated in a phase II randomized trial (NCT01836029) of chemotherapy plus cetuximab in combination with motolimod in patients with recurrent or metastatic HNSCC.

As part of the PRR family, the stimulator of interferon genes (STING) DNA sensing pathway forms an important part of the innate immunity, as it recognizes cytoplasmic DNA through Cyclic GMP-AMP synthase (cGAS), gamma-interferon-inducible protein 16 (IFI16) and probable ATP-dependent RNA helicase (DDX41) (197). Therefore, STING also recognizes tumor-DNA and induces downstream signaling of NF-κB and interferon regulatory factor 3 (IRF-3). This results in the induction IFNs and inflammatory cytokines such as TNF-α, IL-1β and IL-6 (198). However, STING can also induce mitochondrial apoptosis through Bcl-2-associated X protein (Bax) induction (199). Therefore, the use of STING agonists to induce an inflammatory microenvironment and induce direct tumor apoptosis may be a valuable treatment. However, some reports suggest that STING may play a dual role in cancer, potentially promoting tumor growth in tumors with low antigenicity (200). Therefore, combined treatment of STING agonists with other treatments may achieve a good clinical outcome. Interestingly, EGFR was found to affect IRF-3 phosphorylation, suggesting a possibility for cetuximab to be combined with a STING agonist to enhance IRF-3 signaling and thereby lead to an enhanced antitumor response (201). Indeed, STING activation enhanced cetuximab-mediated ADCC of NK cells against HNSCC cell lines and promoted NK : DC crosstalk, suggesting an important role of STING in effective antitumor immunity (202). A phase I trial of the STING agonist dimethylxanthone acetic acid (DMXAA) (murine STING agonist) plus carboplatin, paclitaxel and cetuximab only demonstrated limited activity due to limited binding to human STING (NCT01031212). However, other clinical trials using human counterparts of STING agonists have provided clinical evidence for its therapeutic effectiveness. However, as no phase III trials have been registered yet, it remains to be seen what the exact clinical benefit of this combination will be. Regardless, the accumulated data so far point towards integration of immune-stimulatory molecules into standardized treatment regimens to induce clinically exploitable systemic responses.

Cytokine-Based Immune Potentiation

Cytokines form a group of small short-lived polypeptides that are involved in growth, differentiation and pro- and/or anti-inflammatory signals depending on the cell type. Although usually secreted in response to a defined stimulus, cytokines such as IL-7, required for immune cell homeostasis, can be constitutively expressed as well (203). Additionally, tumor cells can also secrete cytokines, mostly towards the establishment of an immunosuppressive TIME. Exogeneous administration of immunostimulatory cytokines has long been utilized in several lines of immunological investigations as a means of re-establishing the functionality of the immune system.

Interleukin-2 (IL-2)

Characterization of immunosuppressive factors and their involvement in tumor immune escape mechanisms has prompted researchers to reverse these impaired cytotoxic interactions through implementation of immunostimulatory cytokines. A study in HSNCC patients displayed elevated plasma levels TGF-β1 and soluble MHC I chain-related peptide A (sMICA) to diminish NKG2D expression, TNF-α and IFNγ release by NK cells, suppressing their antitumor responses (204). Interestingly, although NKG2D was downregulated due to high sMICA/TGF-β1 levels, CD16 expression and cetuximab-induced ADCC remained unaltered (204). Furthermore, IL-2 stimulation improved ADCC of sMICA inhibited NK cells resulting in a restored TNF-α and IFNγ secretion (204). Similarly, several other investigations in solid tumors have reported a significantly enhanced antitumor activity with tolerable safety profiles and improved ADCC following combined treatment with IL-2 and cetuximab (133, 205, 206). However, IL-2 administration in patients also causes expansion of FoxP3+ Tregs, which highly express the IL-2α receptor (207). Tumor types with relatively low intratumoral Tregs could potentially still benefit from this combination, as shown by the studies above (133, 208, 209). In contrast, tumors such as HNSCC and melanoma have been characterized as the most Treg infiltrated tumor types, making the use of IL-2 in combination with cetuximab less attractive (29, 210). Therefore, the makeup of the TIME is an important consideration that must be evaluated on a tumor type basis for this combination to be of value.

Interleukin-12 (IL-12)

One of the first alternatives to IL-2 was IL-12, a cytokine produced by DCs and macrophages. IL-12 has anti-bacterial and anti-angiogenic effects and enhances the immune response to Ab-coated tumor cells (211). Stimulation of NK cells with IL-12 leads to secretion of IFNγ and TNF-α, as well as increased levels of chemokines such as MIP-1α, IL-8 and RANTES, further stimulating the infiltration of CD8+ T cells into the tumor. Additionally, IL-12 increases IL-2α expression by NK cells, further enhancing NK cell activity in response to endogenous IL-2 (212). A phase I/II trial of heavily pretreated HNSCC patients investigated the combination of IL-12 with cetuximab and achieved stable disease in 69% of patients, with prolonged PFS. Additionally, ADCC responses were increased together with higher levels of IFNγ, CXCL10 and TNF-α secretion (213). IL-12 was also able to suppress Treg function through downregulation of FoxP3 (207, 214). Thus, in addition to stimulating NK cells, IL-12 administration may also reverse immune tolerance and creates a less suppressive TIME, enhancing antitumor immunity.

Interleukin-15 (IL-15)

IL-15 is a cytokine produced primarily by monocytes and macrophages and stimulates various NK and T cell functions (215). Similar to IL-2, stimulation with IL-15 is able to enhance the antitumor effects of NK cells against various tumor types and significantly increases cytokine and chemokine secretions (216, 217). Interestingly, besides upregulation of CD16, NKG2D and IFNγ, levels of NKp30 and NKp46 on NK cells of CRC patients were restored following IL-15 stimulation (216). However, IL-15 based therapies face some limitations as well, including a short serum half-life, narrowing down the therapeutic window, and the requirement for IL-15 receptor α-chain (IL-15Rα)-binding prior to activating effector cells, which limits the therapeutic application (218, 219). More recently, the genetically modified IL-15 compound ALT-803, consisting of IL-15 plus the IL-15Rα fused to the Fc portion of IgG1, has been developed in order to address the limitations of IL-15-based therapies. As a result, ALT-803 has higher biological activity and a longer serum half-life compared with free IL-15. Consistently, ALT-803 was able to enhance the ADCC response following cetuximab treatment in HNSCC cell lines to a level similar to or better than IL-15. In mice, while single-agent treatment partially reduced tumor growth, co-administration of cetuximab with ALT-803 showed complete tumor regression and increased secretion of IFNγ, RANTES and IL-8 (218). Early clinical trials with ALT-803 alone have reported promising efficacy and activity, showing an increased expansion of NK and CD8+ T cells (220). Interestingly, combination of ALT-803 with rituximab, another ADCC inducing mAb, gave similar results as ALT-803 plus cetuximab, thus supporting the exploration of ALT-803 to enhance cetuximab therapy (221).

Interleukin-21 (IL-21)

IL-21 belongs to the IL-2 family of cytokines, based on the shared cytokine receptor γ chain (γc). In comparison to IL-2 and IL-15, single-agent treatment with IL-21 was shown to be the most potent antitumor cytokine with longer lasting responses and clearing mice from tumors in settings where both IL-2 and IL-15 only showed limited effect (222). Additionally, IL-21 stimulation was also shown to increase levels of IL-2α in addition to IFNγ, perforin and GZMB (223). Interestingly, the combination of IL-21 with cetuximab was also able to enhance the ability of NK cells to recognize and eliminate cetuximab-coated tumor cells (223–225). Clinical trials using IL-21 in combination with cetuximab confirm preclinical findings, reporting increased cytokine secretion, enhanced ADCC and achieving stable disease in patients with different tumor types (225, 226).

Although we have discussed the drawback involved in IL-2 treatment regarding Treg expansion, cytokines also have faced criticism as a potential immunotherapeutic approach, due to additional limitations. These include the relatively short serum half-life, requiring careful exploration of clinical doses that could otherwise lead to severe toxic responses (227). Furthermore, IL-2 and IL-12 induce vascular leaking due to alterations in vascular permeability, which is only minimally present with IL-15 and IL-21 treatment (228, 229). These limitations lie at the basis of the functional properties of cytokines. However, they have not stopped researchers from investigating ways to enhance the effectiveness of cytokines through, for example, genetic engineering. The works of Skrombolas et al. and Berraondo et al. provide a detailed and comprehensive review regarding these strategies (203, 208). Taken together, the combined use of cytokines with cetuximab as an ADCC inducing agent has the ability to restore/enhance cytolytic activity of NK cells. Future research likely will include genetically cytokine engineering or consider the use of cytokine cocktails. These could help provide optimal enhancement of NK cells and prevent the limitations involved with single cytokine administration.

Combinations With Immunomodulatory Drugs

Although various novel compounds targeting tumor or immune antigens are in the developmental pipeline, another class of drugs that is of interest are the immunomodulatory drugs. These are a group of small molecules that were initially developed as treatment for other human diseases than cancer but were eventually recognized and exploited for their positive effects on the immune system.

Poly Adenosine Diphosphate (ADP)-Ribose Polymerase (PARP)

Cancer cells rely on DNA damage repair mechanisms to maintain their survival, making these repair pathways ideal targets for cancer treatment, e.g. poly Adenosine diphosphate (ADP)-ribose polymerase (PARP) (230). PARP enzymes act as DNA damage sensors when single-strand DNA breaks occur. Thus, PARP inhibition can severely inhibit cell survival, trigger cell cycle arrest and apoptosis through accumulation of DNA damage. Interestingly, PARP inhibition also activates the STING DNA sensing pathway, subsequently leading to production of type I IFN and pro-inflammatory cytokines, thus priming an antitumor immune response (231, 232). Therefore, the possibility to combine PARP inhibition with immunotherapy seems highly interesting.

EGFR inhibition with cetuximab diminishes DNA synthesis and double-strand break repair and therefore can increase tumor susceptibility to PARP inhibitors (233, 234). Indeed, combining cetuximab with PARP inhibitors significantly increased ADCC in both Breast cancer susceptibility protein (BRCA)-WT and -mutant cell lines (235). Clinically, a phase I study in locally advanced HNSCC patients demonstrated promising responses and tolerable toxicities (236), although results were confounded by continued smoking during treatment of non-responders (237). Thus, this combination warrants further study in a phase II setting to further investigate its effectiveness. The biggest risk involved with PARP inhibition is the potential to develop secondary myelodysplastic syndrome/acute myeloid leukemia due to impaired DNA damage repair. This was limited to patients that additionally received chemotherapy and had germline DNA repair deficiencies, further inducing DNA damage (238).

Thalidomide Derivatives

Despite the severe side effects observed with thalidomide in the 1960s, its mechanisms of action have revealed immunomodulatory and anti-angiogenic activity. Analogues such as lenalidomide and pomalidomide are more potent immunomodulators and have fewer side effects. Lenalidomide has been approved for treatment of multiple hematological malignancies, as it is known to activate cytokine production, regulate T cell co-stimulation and augment NK cell cytotoxicity (239, 240). Lenalidomide is believed to enhance NK cell functionality in an indirect manner, mainly related to the release of IL-2 by other immune cells (240). Lenalidomide also enhanced ADCC following combination with several IgG1 mAbs, including cetuximab (168, 241). So far, the suggested mechanisms report that this enhancement is likely the result of an increased CD16 expression (168) and partly attributable to an increased presence of IL-2 and/or IL-12 cytokines secreted by T cells or other immune cells (242). On the other hand, lenalidomide-enhanced ADCC was abrogated through blocking of either DNAM-1/CD155 interactions or NKG2D with its ligands, indicating that optimal enhancement of ADCC requires interactions of DNAM-1 and NKG2D (168). Clinical trials investigating the combination of lenalidomide with cetuximab are currently in phase I/II and report a well-tolerated treatment with promising clinical activity in patients with CRC and HNSCC. Moreover, a dose-dependent increase in NK cytotoxic activity was demonstrated, with increasing doses of lenalidomide. This was associated with a significantly increased ADCC activity and an increased number of CD8+ T cells and circulating NK cells (243, 244).

Thus, immunomodulating agents such as PARP inhibitors or lenalidomide combined with EGFR-directed therapies show promising preclinical and early clinical results but remain to be investigated in more detail.

Conclusion & Future Perspectives

Although cetuximab is an established therapeutic agent in HNSCC and CRC, a major roadblock in achieving durable responses is the onset of therapeutic resistance. In contrast, immunotherapy can achieve long-lasting disease control, but only in a small percentage of patients. The TIME plays an important role in cancer‐specific drug responses. The recent approval of pembrolizumab as a first-line treatment in HNSCC has sparked an increased interest in the modulation of immune responses to further improve survival of HNSCC patients (245). As increasing evidence points towards immune responses as a major determinant of mAb efficacy, it becomes increasingly difficult not to endorse the rationale of combination therapies. The earliest attempts, for example using IL-2, have indeed enhanced effector functions at the cost of stimulating immunosuppressive cells as well. Current approaches minimize unwanted effects by rational selection of targets such as IL-15. We previously showed that healthy NK cells may overcome cetuximab resistance in vitro (68). However, overcoming clinical resistance to cetuximab may require additional immunotherapies to harness the full potential of NK cells. In this review we have discussed several approaches to augment cetuximab-mediated ADCC against solid tumors.

The majority of approaches discussed in this review focus on manipulation of cell surface receptors and cytokines to enhance NK cell activity. These promising early results warrant further research, as there is a window for improvement and a requirement to tailor these strategies to various tumor types. For example, as HNSCC is marked with the highest infiltration of NK cells, effective treatment should focus on enhancing NK cell activity, by reducing inhibitory signaling or increasing activating signals. In contrast, CRC only shows marginal NK cell infiltration and thus the primary objective should be to lure NK cells inside the tumor, either through adoptive transfer or through increased homing. A better understanding of cancer-specific immune interactions will undoubtedly yield stronger scientific and clinical endeavors.

The current era of genomic, transcriptomic and immune profiling analysis will likely improve the tailoring of single-agent or combination therapies towards patient populations, thus entering an era of precision immunotherapy. Key components towards the success of future trials are considerations towards incorporating ADCC, intratumoral persistence and trafficking of NK cells. In this regard, given the clinical results summarized in this review are mostly still under phase I/II investigation, we anticipate future studies to confirm that cetuximab in combination with immune checkpoint inhibitors synergistically enhances the innate and adaptive antitumor immune responses. There are currently at least 109 active trials investigating cetuximab in a combination regimen with various other treatments (clinicaltrials.gov). Of these, at least 19 trials are investigating combinations with immunotherapeutic modalities discussed above (). The potential of cetuximab-based NK cell immunotherapy looks promising and we foresee that NK cells will become appreciated as a natural component in the fight against cancer.

Table 2

ADCC-mediating IgG1 therapeutic antibodies.

Antibody (Trade name)	Company	Approval FDA/EMA*	Indication	Target	IgG1 type	Fc modification	Reference
Unmodified Fc Abs
Alemtuzumab (Campath)	Ilex Pharmaceuticals	2013	MS	CD52	Humanized	/	(1)
Avelumab (Bavencio)	Merck KGaA and Pfizer	2017	MCC, UC, RCC	PD-L1	Human	/	(2)
Cetuximab (Erbitux)	Bristol-Myers Squibb	2004	HNSCC, CRC	EGFR	Chimeric	/	(3)
Dinutuximab (Unituxin)	United Therapeutics	2015	NB	GD2	Chimeric	/	(4)
Ipilimumab (Yervoy)	Bristol-Myers Squibb	2011	MEL, RCC,	CTLA-4	Human	/	(5)
Necitumumab (Portrazza)	Eli Lilly and Company	2015/2016	NSCLC	EGFR	Human	/	(6)
Ofatumumab (Arzerra)	Genmab	2009/2010	CLL	CD20	Human	/	(7)
Pertuzumab (Perjeta)	Genentech	2012/2013	BCA	HER2/neu	Humanized	/	(8)
Rituximab (Rituxan)	Genentech	1997/1998	NHL, CLL	CD20	Chimeric	/	(9)
Trastuzumab (Herceptin)	Genentech	1998/2000	BCA, GC	HER2/neu	Humanized	/	(10)
Fc modified Abs
Imgatuzumab	Genentech	/	HNSCC	EGFR	Humanized	Reduced fucosylation	(11)
Margetuximab (Margenza)	MacroGenics	2020/2018	BCA	HER2/neu	Chimeric	Enhanced FcγRIII binding (F243L; R292P; Y300L; V305I; P396L)	(12)
Mogamulizumab (Poteligeo)	Kyowa Hakko Kirin	2018	CTCL	CCR4	Humanized	Afucosylated	(13)
Obinutuzumab (Gazyva)	Roche	2013/2014	CLL, FL	CD20	Humanized	Afucosylated	(14)
Tafasitamab (Monjuvi)	MorphoSys	2020	DLBCL	CD19	Humanized	Enhanced FcγRIII binding (S239D; I332E)	(15)
Tomuzotuximab (CetuGEX)	Glycotope	/	NSCLC, CRC, HNSCC, GC	EGFR	Chimeric	Afucosylated	(16)

BCA, Breast cancer; CCR4, Chemokine receptor 4; CLL, Chronic lymphocytic leukemia; CRC, Colorectal cancer; CTCL, Cutaneous T-cell lymphoma; CTLA-4, Cytotoxic T-lymphocyte-associated protein 4; DLBCL, Diffuse large B-cell lymphoma; EGFR, Epidermal growth factor receptor; EMA, European Medicines Agency; FDA, Food and Drug Administration; FL, Follicular lymphoma; GC, Gastric cancer; GD2, Disialoganglioside; HER, Epidermal growth factor receptor 2; HNSCC, Head and neck squamous cell carcinoma; I.V., Intravenously; MCC, Merkel cell carcinoma; MEL, Melanoma; MS, Multiple sclerosis; NB, Neuroblastoma; NSCLC, Non-small cell lung cancer; RCC, Renal cell carcinoma; UC, urothelial carcinoma.*Approval by FDA and EMA within the same year if only a single date is given.

Although we exclusively discussed cetuximab as the primary ADCC-inducing agent in this review, a large portion of these applications could be applied to other IgG1 mAbs (). In this regard, we believe the NK cell-based discussed approaches could also be of interest for other cancer indications employing ADCC-inducing mAbs. Moreover, growing research focuses on the development of engineered mAbs that display enhanced ADCC. These modifications involve altering the mAb Fc portion to increase binding affinity to FcγRIIIa via site-directed mutagenesis, editing Fc domain glycosylation and/or removing Fc domain fucosylation. Various Fc-engineered mAbs have shown improved responses compared to unmodified counterparts and have gained approval for clinical use ().

Table 3

Active clinical trials evaluating cetuximab in combination with NK cell stimulating immunotherapies.

Clinical trial ID	Study phase	Estimated patients	Initial registration	Indication	Treatment	Primary endpoint	Status
Adoptive NK cell therapy
NCT03319459	I	100	2018	Advanced Solid Tumors	FATE-NK100	DLT	Active, not recruiting
					FATE-NK100 + trastuzumab
					FATE-NK100 + cetuximab
NCT04872634	I/II	24	2021	LA/M NSCLC	SNK01 (low/high dose) + gemcitabin e	MTD, AE	Recruiting
					SNK01 (low/high) + Cetuximab + gemcitabin e
Cytokines
NCT01468896	I/II	23	2011	R/M HNSCC	Recombinant interleukin-12 + cetuximab	DLT, OR	Active, not recruiting
NCT02627274	I	134	2015	Solid tumors	RO6874281	DLT, MTD, OBD	Active, not recruiting
					RO6874281 + Trastuzumab
					RO6874281 + cetuximab
NCT04616196	I/II	78	2020	R/M HNSCC & CRC	Dose Escalation of NKTR-255 + cetuximab	AE, ORR	Recruiting
					Dose expansion of NKTR-255 + cetuximab
EGFR-TKI
NCT02716311	II	118	2016	EGFR mutant NSCLC	Afatinib	TTF	Active, not recruiting
					Afatinib + cetuximab
NCT02979977	II	50	2016	Advanced HNSCC	Afatinib + cetuximab	ORR	Recruiting
NCT03727724	II	37	2018	NSCLC	Afatinib + cetuximab	DCR	Recruiting
NCT04820023	I/II	90	2021	Advance d NSCLC	BBT-176	AE, DLT, ORR	Recruiti ng
					BBT-176 + cetuximab
NKG2A
NCT02643550	I/II	143	2015	R/M HNSCC	Monalizumab + cetuximab	DLT, ORR	Active, not recruitin g
					monalizumab + cetuximab + anti-PD(L)1
NCT04349267	I/II	308	2020	Advanced Solid	BMS-986315	AE	Recruiti
				Tumors	BMS-986315 + nivolumab		ng
					BMS-986315 + cetuximab
NCT04590963	III	600	2020	R/M HNSCC	Monalizumab + cetuximab	OS	Recruiting
					Placebo + cetuximab
PD-1/PD-L1
NCT02999087	III	707	2016	LA HNSCC	CRT	PFS	Active, not recruiting
					Cetuximab + RT + avelumab
NCT03174405	II	43	2017	mCRC	Avelumab + cetuximab + FOLFOX	PFS	Active, not recruiting
NCT03494322	II	130	2018	R/M HNSCC	Avelumab	DLT, DCR	not recruiting
					Avelumab + cetuximab
NCT03498378	I	24	2018	R/M HNSCC	Avelumab + cetuximab + palbociclib	MTD	Recruiting
NCT03608046	II	59	2018	mCRC	Avelumab + cetuximab + irinotecan	ORR	Recruiting
NCT03944252	II	54	2018	LA & R/M SCCAC	Avelumab	ORR	Active, not recruiting
					Avelumab + cetuximab
NCT04561336	II	77	2018	RAS-WT mCRC	Avelumab + cetuximab	OS	Active, not recruiting

AE, Adverse events, CR, Complete response, CRT, Chemoradiotherapy, CSCC, Cutaneous squamous cell cancer, DCR, Disease control rate, DLT, Dose limiting toxicity, ESqCC, Esophageal squamous cell carcinoma, HNSCC, head and neck squamous cell carcinoma, LA, Locally advanced, mCRC, Metastatic colorectal carcinoma, MTD, Maximum tolerated dose, OBD, Optimal biological dose, OR, Objective response, ORR, Objective response rate, OS, Overall survival, PFS, Progression free survival, R/M, Recurrent and metastatic, RT, radiotherapy, SCCAC, Squamous cell anal carcinoma, TTF, Time to treatment failure, WT, Wild-type.

Implementation of any combination treatment requires a strong consideration for potential AEs. Biomarkers for EGFR targeting include EGFR gene amplifications and mutations, but also downstream sarcoma viral oncogene (Ras), PI3K and PTEN activities as well (102, 246). As downstream oncogenic signaling can affect the TIME, it is important to consider immunological biomarkers as well. Besides PD-L1 expression on tumors, factors such as PD-L1 on immune cells and co-expression of other inhibitory checkpoints may affect the response to PD-1 targeting (247). Furthermore, consideration of tumor immune infiltration, proportion of immune cell phenotypes and tumor mutational burden have proven to be a better representation for the effectiveness of immunotherapies in solid tumors (40, 248–250).

Importantly, despite the overall success of immune checkpoint inhibitors in various tumor types, meta-analyses often show severe treatment-related AEs that are associated with tumor response. In most patients, these AEs are related to overstimulation of immune reactivity. However, the severity of AEs is dependent on the used inhibitor. For example, CTLA-4 inhibitors have a higher risk of treatment-related AEs compared to PD-1/PD-L1 inhibitors (251). A possible solution might be targeting several biological pathways to induce longer-lasting responses. Interestingly, while the use of dual checkpoint inhibition or combination with TKI increased dose-sensitivity with higher risk of toxicity, mAb combinations, including cetuximab, that aim to elicit higher ADCC responses could be given at their recommended phase II doses without greatly increasing toxicities (252). Nevertheless, future research should always consider the potential for increased AEs in any combination strategy and dose-escalation schemes are greatly useful in that regard.

The next couple of years will undoubtedly bring a more in-depth understanding of the TIME together with the next generation of targets for anticancer treatment. This will allow us to rationally design better combination therapies in order to achieve the most optimal long-term effectiveness. In this era, we believe that cetuximab and many other ADCC-capable mAbs will remain valuable components, as it becomes clear that mAbs can add great benefit to both conventional and immunotherapies. As NK cell activation depends on a balance of stimulatory and inhibitory signals, the combinations that involve stimulation of NK cells through ADCC, together with suppression of inhibitory signals or the attraction of NK cells are of particular interest. As these combinations are currently under (pre)clinical investigation, the knowledge they provide regarding valuable biomarkers will soon guide the next generation of clinical trial measurements and ultimately lead to higher-quality treatments that will provide the most effective benefit to the patient.

Author Contributions

HB, JDW, IDP, JBV, and AW conceived the presented idea. The writing of the presented work was supervised by JW, IP, and AW. The original draft was written by HB and reviewed & edited by HB, JW, IP, HZ, MP, JV, FL, and AW. All authors contributed to the article and approved the submitted version. All figures were created using BioRender.com

Funding

The research was funded by Kom op tegen Kanker with grant number OZ7886 (Stand up to Cancer), the Flemish cancer society.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.